SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap's stock is surging as investors react to a Q3 earnings beat, a $500 million stock buyback, and a new $400 million AI partnership with Perplexity. The community is buzzing about the potential for a short squeeze and upgraded price targets, while also weighing concerns about profitability and the long-term sustainability of the rally.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending as investors anticipate upcoming earnings results, with many in the community expecting strong numbers driven by growth and the Alani Nu acquisition. Despite overall market uncertainty, the community expresses long-term confidence in CELH's execution and potential, while also closely monitoring potential short-term volatility and market manipulation.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors anticipate Phase 3 data for their DMD treatment, deramiocel, expected mid-Q4, with the community actively discussing potential FDA approval pathways. Discussions also involve the StealthX exosome platform and recent job postings at Capricor and NS Pharma, hinting at possible positive outcomes. Community members are closely monitoring short interest and options activity, speculating on potential market reactions following the data release.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending as traders assess the semiconductor sector's near-term trajectory amidst AI optimism and US-China trade concerns. Community discussions include reactions to earnings reports from key semiconductor companies and speculation about upcoming economic data releases and Federal Reserve actions. Bullish sentiment persists, while some are wary of overvaluation and the potential for a pullback.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending amid speculation about potential partnerships or a buyout, with an earlier earnings call fueling anticipation. Community members are debating the likelihood of a deal, with some eyeing AstraZeneca as a possible partner, while others express skepticism and frustration with management. Bullish sentiment is building as some traders position for a potential breakout and short squeeze ahead of earnings.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT) is trending as community members discuss its tokenomics, specifically the locked dev tokens until February and scheduled buybacks, which some believe will naturally increase the coin price.  Concerns about competitors potentially suppressing the token's price and calls for fair play are also circulating.  Traders are actively watching key price levels and anticipating potential volatility, with some suggesting it's time for a rebound.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is trending as the community discusses its potential for future growth and staking opportunities. Many users are accumulating and staking $SWEAT, motivated by the project's concept of earning crypto through walking and its potential for long-term gains. The conversation also highlights anticipation for increased utility and adoption of the Sweat Wallet in the US.

Caledonia Mining Corp. Plc engages in the exploration, development, and production of gold and other precious metals from its mineral properties. Its projects include Blanket Gold Mine and Maligreen. The company was founded on February 5, 1992 and is headquartered in St. Helier, the United Kingdom.

Caledonia Mining Corporation Plc

Caledonia Mining Corporation ($CMCL) is trending due to upcoming earnings and discussions around its potential growth, particularly the Bilboes project which could significantly increase production; the earnings are scheduled to be released Monday before the market opens. Community members are weighing the company's profitability against the political risks of operating in Zimbabwe, with some anticipating a positive impact from rising gold prices and others concerned about potential dilution from financing activities. Recent discussions also touch on the stock's valuation relative to its growth potential and comparison to other gold miners.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

DVAX is trending due to a new $100 million share buyback program and updates regarding a partnership with VXRT for a novel oral COVID-19 vaccine. The community is discussing the potential financial benefits and strategic implications of this agreement, as well as concerns about delays in the FDA study protocol for HLAD in adults on hemodialysis. Investors are also weighing in on the impact of Deep Track's involvement and management's capital allocation decisions.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is trending amid discussions about its post-earnings drop, despite reporting strong revenue and user growth, as the market reacts to future guidance and broader concerns about growth pace and AI competition. The community is debating whether the dip is an overreaction and a buying opportunity or a sign of deeper issues with the company's valuation and long-term prospects. Some traders are anticipating a potential bounce, while others believe the stock could fall further.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced on Thursday that the U.S. Food and Drug Administration has approved a generic version of the Liraglutide injection known as Saxenda.Liraglutide Injection is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated to reduce excess body weight and maintain weight reduction long-term in adults as well as pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. The drug is to be used in combination with a reduced-calorie diet and increased physical activity.“With this approval, and by launching a generic for Saxenda (liraglutide injection), we will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss,” <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.tevapharm.com/news-and-media/latest-news/teva-announces-fda-approval-and-launch-of-generic-saxenda-liraglutide-injection--first-generic-glp-1-/">said</a> Ernie Richardsen, Head of U.S. Commercial Generics at Teva. He added that it marks an important addition to the company’s generics portfolio.Saxenda, Novo Nordisk’s older obesity drug, had annual sales of $165 million as of June 2025, the company said. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TEVA">TEVA stock</a> trended within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_28_at_9_52_29_AM_png_ba7ec14e95.webp" alt="TEVA's Sentiment Meter and Message Volume as of 9:52 a.m. ET on Aug. 28, 2025 | Source: Stocktwits" width="625" height="64"><figcaption>TEVA's Sentiment Meter and Message Volume as of 9:52 a.m. ET on Aug. 28, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed surprise that the stock is not trading higher despite the approval.<stembedurl>https://stocktwits.com/RemitTekram/message/626845403</stembedurl>Another user sounded skeptical, saying that the stock would probably end the day in the red despite “explosive news.”<stembedurl>https://stocktwits.com/NoTradeAnymore/message/626842741</stembedurl>In the second quarter, Teva recorded revenue of $4.2 billion and adjusted and diluted earnings per share of $0.66. Generics product revenues in the U.S., however, fell 6% to $961 million, due to lower revenues from Lenalidomide capsules, the generic version of Revlimid, and Liraglutide injection 1.8mg, an authorized generic of Victoza, primarily driven by increased competition.TEVA stock is down 19% this year and approximately 3% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/lakeshore-biopharma-receives-revised-proposal-to-acquire-company/chs6JRRRdmm">LakeShore Biopharma Receives Revised Proposal To Acquire Company</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A very overweight woman with swollen feet stands on a scale that reads 145.1 kilograms. Overweight and obesity are increasing at a rapid pace worldwide. Photo: Pia Bayer/dpa (Photo by Pia Bayer/picture alliance via Getty Images)

This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More

The company’s U.S. affiliate announced that the U.S. Food and Drug Administration has approved a generic version of Liraglutide injection, known as Saxenda.

IYLD
iShares Morningstar Multi-Asset Income ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IYLD News

IYLDiShares Morningstar Multi-Asset Income ETF